Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01690195 · ClinicalTrials.gov registry record · Phase 2
Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease
A Phase 2 study, sponsored by AbbVie (prior sponsor, Abbott).
- Terminated
- Registry status
- Phase 2
- Development phase
- 343
- Enrollment target
NCT01690195 is a Phase 2 study that was terminated before completion, run by AbbVie (prior sponsor, Abbott). The registered enrollment target is 343 participants.
The verdict
NCT01690195, a Phase 2 study, was terminated before completion, sponsored by AbbVie (prior sponsor, Abbott).
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 343 participants
- Enrollment target
Study Summary
This is a long term extension study to evaluate safety and tolerability of subjects who complete study M11-793 which is evaluating a new treatment for subjects with mild to moderate Alzheimer's disease on stable doses of acetylcholinesterase inhibitors.
Interventions
- DRUG ABT-126
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 343 participants |
| Start Date | 2012-09 |
| Est. Completion | 2014-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01690195
The ClinicalTrials.gov registry entry for NCT01690195 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 343 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie (prior sponsor, Abbott), which has 88 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ABT-126 is the first listed.
NCT01690195 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01690195 about?
NCT01690195 is a clinical study titled "Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease". This is a long term extension study to evaluate safety and tolerability of subjects who complete study M11-793 which is evaluating a new treatment for subjects with mild to moderate Alzheimer's disease on stable doses of acetylcholinesterase inhibitors.
What is the current status of trial NCT01690195?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 343 participants. The study started on 2012-09. Estimated completion is 2014-02.
What interventions are being tested in trial NCT01690195?
The interventions under investigation include: ABT-126 (DRUG).
Who is sponsoring clinical trial NCT01690195?
This trial is sponsored by AbbVie (prior sponsor, Abbott), which has 88 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.